{"id":57146,"date":"2026-02-14T11:08:44","date_gmt":"2026-02-14T03:08:44","guid":{"rendered":"https:\/\/flcube.com\/?p=57146"},"modified":"2026-02-14T11:08:45","modified_gmt":"2026-02-14T03:08:45","slug":"3sbios-amdokitug-wins-nmpa-approval-for-moderate-to-severe-plaque-psoriasis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57146","title":{"rendered":"3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis"},"content":{"rendered":"\n

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.<\/strong> (SHA:\u202f688336<\/a><\/strong>), a subsidiary of 3SBio Inc.<\/strong> (HKG:\u202f1530<\/a><\/strong>), announced that Amdokitug (Yisaituo)<\/strong>, its independently developed anti-IL-17A humanized monoclonal antibody<\/strong>, has received NMPA approval<\/strong> for adult patients with moderate-to-severe plaque psoriasis<\/strong> eligible for systemic therapy or phototherapy<\/strong>. The Category 1 biological product<\/strong>, featuring optimized immunogenicity screening<\/strong> to reduce anti-drug antibody (ADA) formation<\/strong>, demonstrated superior skin clearance rates (PASI 100)<\/strong> and durable efficacy<\/strong> in Phase 3 studies<\/strong>, positioning as a next-generation IL-17A inhibitor<\/strong> in China’s rapidly expanding immunology market<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Sunshine Guojian Pharmaceutical (3SBio subsidiary, SHA:\u202f688336, HKEX:\u202f1530)<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Asset<\/strong><\/td>Amdokitug (Yisaituo) \u2013 Anti-IL-17A humanized monoclonal antibody<\/td><\/tr>
Classification<\/strong><\/td>Category 1 biological product<\/strong> (innovative biologic)<\/td><\/tr>
Approved Indication<\/strong><\/td>Moderate-to-severe plaque psoriasis (systemic therapy\/phototherapy candidates)<\/td><\/tr>
Differentiation<\/strong><\/td>Optimized molecular sequence<\/strong> for reduced immunogenicity\/ADA formation<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 Phase 3 Study Results<\/h2>\n\n\n\n
Endpoint<\/th>Amdokitug Performance<\/th>Clinical Significance<\/th><\/tr><\/thead>
Primary Endpoints<\/strong><\/td>PASI 75 and sPGA 0\/1 achieved<\/strong><\/td>Standard efficacy benchmarks met<\/td><\/tr>
Key Secondary Endpoints<\/strong><\/td>PASI 90, PASI 100, sPGA 0 achieved<\/strong><\/td>Superior complete skin clearance<\/strong><\/td><\/tr>
PASI 100 (Complete Clearance)<\/strong><\/td>Excellent response rates<\/strong> \u2013 induction (12 weeks) and maintenance (52 weeks)<\/td>Best-in-class potential<\/strong> for total skin clearance<\/td><\/tr>
Onset Speed<\/strong><\/td>Rapid<\/strong><\/td>Early patient satisfaction; reduced treatment switching<\/td><\/tr>
Durability<\/strong><\/td>52-week maintenance efficacy sustained<\/strong><\/td>Long-term disease control; adherence advantage<\/td><\/tr>
Safety Profile<\/strong><\/td>Favorable<\/strong>; low ADA formation<\/strong><\/td>Reduced immunogenicity risk<\/strong>; long-term tolerability<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Positioning & Market Context<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
China Psoriasis Market<\/strong><\/td>>6 million patients<\/strong> with moderate-to-severe disease; IL-17A class<\/strong> (secukinumab, ixekizumab) rapidly displacing TNF inhibitors<\/strong> due to superior skin clearance<\/strong><\/td><\/tr>
Amdokitug Differentiation<\/strong><\/td>Optimized immunogenicity<\/strong> addresses ADA-mediated loss of efficacy<\/strong> seen with originator secukinumab<\/strong>; potential for sustained long-term response<\/strong><\/td><\/tr>
3SBio Immunology Franchise<\/strong><\/td>Amdokitug anchors autoimmune portfolio<\/strong>; complements 3SBio’s existing biologics<\/strong> (TNF inhibitors, IL-6 blockers); integrated dermatology and rheumatology commercial infrastructure<\/strong><\/td><\/tr>
Category 1 Status<\/strong><\/td>Innovative biologic designation<\/strong> provides market exclusivity<\/strong>, NRDL listing priority<\/strong>, and regulatory fast-track<\/strong> for additional indications<\/strong> (PsA, AS)<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Novartis Cosentyx (secukinumab)<\/strong> and Eli Lilly Taltz (ixekizumab)<\/strong> established; Amdokitug domestic manufacturing and pricing<\/strong> enables market share capture<\/strong> and NRDL competitiveness<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercial Outlook<\/h2>\n\n\n\n
Priority<\/th>Execution Plan<\/th>Timeline<\/th><\/tr><\/thead>
Launch<\/strong><\/td>Hospital dermatology access; key opinion leader engagement; patient education<\/td>Q1-Q2\u202f2026<\/td><\/tr>
NRDL Negotiation<\/strong><\/td>National Reimbursement Drug List inclusion for psoriasis<\/td>2026-2027<\/td><\/tr>
Label Expansion<\/strong><\/td>Psoriatic arthritis (PsA), ankylosing spondylitis (AS) submissions<\/td>2026-2027<\/td><\/tr>
Manufacturing Scale<\/strong><\/td>GMP facility optimization; cost reduction for competitive pricing<\/td>2026-2027<\/td><\/tr>
Global Potential<\/strong><\/td>Ex-China partnership discussions; regulatory pathway evaluation<\/td>2027+<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Amdokitug commercial launch success, NRDL reimbursement outcomes, and competitive positioning vs. secukinumab and ixekizumab in China. Actual results may differ due to pricing pressure from national procurement programs, physician prescribing habits, and immunogenicity profile validation in real-world use.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA:\u202f688336), a subsidiary of 3SBio Inc. (HKG:\u202f1530), announced that…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[116,1061,15,1553,398],"class_list":["post-57146","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-3sbio","tag-hkg-1530","tag-product-approvals","tag-sha-688336","tag-sunshine-guojian-pharmaceutical"],"yoast_head":"\n3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA:\u202f688336), a subsidiary of 3SBio Inc. (HKG:\u202f1530), announced that Amdokitug (Yisaituo), its independently developed anti-IL-17A humanized monoclonal antibody, has received NMPA approval for adult patients with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. The Category 1 biological product, featuring optimized immunogenicity screening to reduce anti-drug antibody (ADA) formation, demonstrated superior skin clearance rates (PASI 100) and durable efficacy in Phase 3 studies, positioning as a next-generation IL-17A inhibitor in China's rapidly expanding immunology market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57146\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis\" \/>\n<meta property=\"og:description\" content=\"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA:\u202f688336), a subsidiary of 3SBio Inc. (HKG:\u202f1530), announced that Amdokitug (Yisaituo), its independently developed anti-IL-17A humanized monoclonal antibody, has received NMPA approval for adult patients with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. The Category 1 biological product, featuring optimized immunogenicity screening to reduce anti-drug antibody (ADA) formation, demonstrated superior skin clearance rates (PASI 100) and durable efficacy in Phase 3 studies, positioning as a next-generation IL-17A inhibitor in China's rapidly expanding immunology market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57146\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-14T03:08:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-14T03:08:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57146#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57146\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis\",\"datePublished\":\"2026-02-14T03:08:44+00:00\",\"dateModified\":\"2026-02-14T03:08:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57146\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"3SBio\",\"HKG: 1530\",\"Product approvals\",\"SHA: 688336\",\"Sunshine Guojian Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57146#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57146\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57146\",\"name\":\"3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-14T03:08:44+00:00\",\"dateModified\":\"2026-02-14T03:08:45+00:00\",\"description\":\"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA:\u202f688336), a subsidiary of 3SBio Inc. (HKG:\u202f1530), announced that Amdokitug (Yisaituo), its independently developed anti-IL-17A humanized monoclonal antibody, has received NMPA approval for adult patients with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. The Category 1 biological product, featuring optimized immunogenicity screening to reduce anti-drug antibody (ADA) formation, demonstrated superior skin clearance rates (PASI 100) and durable efficacy in Phase 3 studies, positioning as a next-generation IL-17A inhibitor in China's rapidly expanding immunology market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57146#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57146\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57146#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis - Insight, China's Pharmaceutical Industry","description":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA:\u202f688336), a subsidiary of 3SBio Inc. (HKG:\u202f1530), announced that Amdokitug (Yisaituo), its independently developed anti-IL-17A humanized monoclonal antibody, has received NMPA approval for adult patients with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. The Category 1 biological product, featuring optimized immunogenicity screening to reduce anti-drug antibody (ADA) formation, demonstrated superior skin clearance rates (PASI 100) and durable efficacy in Phase 3 studies, positioning as a next-generation IL-17A inhibitor in China's rapidly expanding immunology market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57146","og_locale":"en_US","og_type":"article","og_title":"3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis","og_description":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA:\u202f688336), a subsidiary of 3SBio Inc. (HKG:\u202f1530), announced that Amdokitug (Yisaituo), its independently developed anti-IL-17A humanized monoclonal antibody, has received NMPA approval for adult patients with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. The Category 1 biological product, featuring optimized immunogenicity screening to reduce anti-drug antibody (ADA) formation, demonstrated superior skin clearance rates (PASI 100) and durable efficacy in Phase 3 studies, positioning as a next-generation IL-17A inhibitor in China's rapidly expanding immunology market.","og_url":"https:\/\/flcube.com\/?p=57146","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-14T03:08:44+00:00","article_modified_time":"2026-02-14T03:08:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57146#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57146"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis","datePublished":"2026-02-14T03:08:44+00:00","dateModified":"2026-02-14T03:08:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57146"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["3SBio","HKG: 1530","Product approvals","SHA: 688336","Sunshine Guojian Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57146#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57146","url":"https:\/\/flcube.com\/?p=57146","name":"3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-14T03:08:44+00:00","dateModified":"2026-02-14T03:08:45+00:00","description":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA:\u202f688336), a subsidiary of 3SBio Inc. (HKG:\u202f1530), announced that Amdokitug (Yisaituo), its independently developed anti-IL-17A humanized monoclonal antibody, has received NMPA approval for adult patients with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. The Category 1 biological product, featuring optimized immunogenicity screening to reduce anti-drug antibody (ADA) formation, demonstrated superior skin clearance rates (PASI 100) and durable efficacy in Phase 3 studies, positioning as a next-generation IL-17A inhibitor in China's rapidly expanding immunology market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57146#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57146"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57146#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"3SBio\u2019s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57146"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57146\/revisions"}],"predecessor-version":[{"id":57147,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57146\/revisions\/57147"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}